UNSPSC 51371602: Betametadol or betamethadol

This classification denotes an opioid receptor agonist with the molecular formula C21H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57ANR1Z628, chemically known as 6-dimethylamino-4,4-diphenyl-3-heptanol, hydrochloride but generally known as betamethadol, which bears US NIH Compound Identifier 28397. European Medicines Agency schedules Betamethadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05796MIG. The term BETAMETHADOL is an International Non-Proprietary Name.

BETAMETHADOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Betametadol or betamethadol bears US NLM identifiers UMLS ID C2698379 and NCI Concept Code C77279. SMILES: OC(C(CC(N(C)C)C)(C1CCCCC1)C1CCCCC1)CC.

UNSPSC 51371602 Betametadol or betamethadol is a Commodity code that in practice covers prescription pharmaceuticals and related pharmaceutical products procured by state and local health agencies, though recent solicitations under this code tag show minimal direct alignment with the code's nominal scope. State and local governments use codes in this family to procure generic pharmaceuticals, opioid-reversal medications, and over-the-counter products through centralized purchasing mechanisms, often leveraging cooperative agreements and authorized wholesale distribution channels. Issuing bodies include state health and human services departments, county health systems, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions to negotiate volume-based pricing and ensure consistent supply to clinics, community health centers, and emergency-response programs.

Recent activity spans multiple states and procurement models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, with responses due March 26, 2026, seeking manufacturers of generic pharmaceuticals and OTC products for distribution across participating state and local facilities in Minnesota, Oregon, and other member jurisdictions; the contract runs two years with optional extensions through June 30, 2028. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and wholesaler arrangements. The code shows activity concentrated in cooperative purchasing vehicles and state health agency procurement, with no explicit small-business or disadvantaged-enterprise set-asides noted in recent solicitations.